Blueprint Medicines Corp Stock Market Value
| BPMC Stock | USD 114.05 0.27 0.24% |
| Symbol | Blueprint |
Blueprint Medicines Corp Price To Book Ratio
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Blueprint Medicines. If investors know Blueprint will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Blueprint Medicines listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (2.09) | Revenue Per Share | Quarterly Revenue Growth 1.266 | Return On Assets | Return On Equity |
The market value of Blueprint Medicines Corp is measured differently than its book value, which is the value of Blueprint that is recorded on the company's balance sheet. Investors also form their own opinion of Blueprint Medicines' value that differs from its market value or its book value, called intrinsic value, which is Blueprint Medicines' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Blueprint Medicines' market value can be influenced by many factors that don't directly affect Blueprint Medicines' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Blueprint Medicines' value and its price as these two are different measures arrived at by different means. Investors typically determine if Blueprint Medicines is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Blueprint Medicines' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Blueprint Medicines 'What if' Analysis
In the world of financial modeling, what-if analysis is part of sensitivity analysis performed to test how changes in assumptions impact individual outputs in a model. When applied to Blueprint Medicines' stock what-if analysis refers to the analyzing how the change in your past investing horizon will affect the profitability against the current market value of Blueprint Medicines.
| 01/01/2025 |
| 01/31/2025 |
If you would invest 0.00 in Blueprint Medicines on January 1, 2025 and sell it all today you would earn a total of 0.00 from holding Blueprint Medicines Corp or generate 0.0% return on investment in Blueprint Medicines over 30 days. Blueprint Medicines is related to or competes with Terns Pharmaceuticals, Amylyx Pharmaceuticals, Acumen Pharmaceuticals, Inozyme Pharma, X4 Pharmaceuticals, PTC Therapeutics, and Krystal Biotech. Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blo... More
Blueprint Medicines Upside/Downside Indicators
Understanding different market momentum indicators often help investors to time their next move. Potential upside and downside technical ratios enable traders to measure Blueprint Medicines' stock current market value against overall market sentiment and can be a good tool during both bulling and bearish trends. Here we outline some of the essential indicators to assess Blueprint Medicines Corp upside and downside potential and time the market with a certain degree of confidence.
| Downside Deviation | 2.44 | |||
| Information Ratio | 0.1294 | |||
| Maximum Drawdown | 19.12 | |||
| Value At Risk | (3.53) | |||
| Potential Upside | 5.87 |
Blueprint Medicines Market Risk Indicators
Today, many novice investors tend to focus exclusively on investment returns with little concern for Blueprint Medicines' investment risk. Other traders do consider volatility but use just one or two very conventional indicators such as Blueprint Medicines' standard deviation. In reality, there are many statistical measures that can use Blueprint Medicines historical prices to predict the future Blueprint Medicines' volatility.| Risk Adjusted Performance | 0.1405 | |||
| Jensen Alpha | 0.4412 | |||
| Total Risk Alpha | 0.1628 | |||
| Sortino Ratio | 0.1777 | |||
| Treynor Ratio | 0.5703 |
Blueprint Medicines Corp Backtested Returns
Blueprint Medicines appears to be very steady, given 3 months investment horizon. Blueprint Medicines Corp secures Sharpe Ratio (or Efficiency) of 0.12, which signifies that the company had a 0.12 % return per unit of risk over the last 3 months. We have found twenty-eight technical indicators for Blueprint Medicines Corp, which you can use to evaluate the volatility of the firm. Please makes use of Blueprint Medicines' Risk Adjusted Performance of 0.1405, downside deviation of 2.44, and Mean Deviation of 2.08 to double-check if our risk estimates are consistent with your expectations. On a scale of 0 to 100, Blueprint Medicines holds a performance score of 9. The firm shows a Beta (market volatility) of 0.92, which signifies possible diversification benefits within a given portfolio. Blueprint Medicines returns are very sensitive to returns on the market. As the market goes up or down, Blueprint Medicines is expected to follow. Please check Blueprint Medicines' expected short fall, day median price, and the relationship between the potential upside and accumulation distribution , to make a quick decision on whether Blueprint Medicines' price patterns will revert.
Auto-correlation | 0.48 |
Average predictability
Blueprint Medicines Corp has average predictability. Overlapping area represents the amount of predictability between Blueprint Medicines time series from 1st of January 2025 to 16th of January 2025 and 16th of January 2025 to 31st of January 2025. The more autocorrelation exist between current time interval and its lagged values, the more accurately you can make projection about the future pattern of Blueprint Medicines Corp price movement. The serial correlation of 0.48 indicates that about 48.0% of current Blueprint Medicines price fluctuation can be explain by its past prices.
| Correlation Coefficient | 0.48 | |
| Spearman Rank Test | 0.43 | |
| Residual Average | 0.0 | |
| Price Variance | 10.85 |
Blueprint Medicines Corp lagged returns against current returns
Autocorrelation, which is Blueprint Medicines stock's lagged correlation, explains the relationship between observations of its time series of returns over different periods of time. The observations are said to be independent if autocorrelation is zero. Autocorrelation is calculated as a function of mean and variance and can have practical application in predicting Blueprint Medicines' stock expected returns. We can calculate the autocorrelation of Blueprint Medicines returns to help us make a trade decision. For example, suppose you find that Blueprint Medicines has exhibited high autocorrelation historically, and you observe that the stock is moving up for the past few days. In that case, you can expect the price movement to match the lagging time series.
Current and Lagged Values |
| Timeline |
Blueprint Medicines regressed lagged prices vs. current prices
Serial correlation can be approximated by using the Durbin-Watson (DW) test. The correlation can be either positive or negative. If Blueprint Medicines stock is displaying a positive serial correlation, investors will expect a positive pattern to continue. However, if Blueprint Medicines stock is observed to have a negative serial correlation, investors will generally project negative sentiment on having a locked-in long position in Blueprint Medicines stock over time.
Current vs Lagged Prices |
| Timeline |
Blueprint Medicines Lagged Returns
When evaluating Blueprint Medicines' market value, investors can use the concept of autocorrelation to see how much of an impact past prices of Blueprint Medicines stock have on its future price. Blueprint Medicines autocorrelation represents the degree of similarity between a given time horizon and a lagged version of the same horizon over the previous time interval. In other words, Blueprint Medicines autocorrelation shows the relationship between Blueprint Medicines stock current value and its past values and can show if there is a momentum factor associated with investing in Blueprint Medicines Corp.
Regressed Prices |
| Timeline |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Blueprint Medicines Corp offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Blueprint Medicines' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Blueprint Medicines Corp Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Blueprint Medicines Corp Stock:Check out Blueprint Medicines Correlation, Blueprint Medicines Volatility and Blueprint Medicines Alpha and Beta module to complement your research on Blueprint Medicines. You can also try the Crypto Correlations module to use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins.
Blueprint Medicines technical stock analysis exercises models and trading practices based on price and volume transformations, such as the moving averages, relative strength index, regressions, price and return correlations, business cycles, stock market cycles, or different charting patterns.